Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Journal
-
- The Lancet Oncology
-
The Lancet Oncology 17 (2), 234-242, 2016-02
Elsevier BV
- Tweet
Details 詳細情報について
-
- CRID
- 1360574094484237312
-
- ISSN
- 14702045
-
- Data Source
-
- Crossref